ObsEva (CHIX:OBSNZ) EBIT per Share : CHF-0.29 (TTM As of Dec. 2022)

View and export this data going back to 2018. Start your Free Trial

What is ObsEva EBIT per Share?

ObsEva's EBIT per Share for the three months ended in Dec. 2022 was CHF0.27. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 was CHF-0.29.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for ObsEva's EBIT per Share or its related term are showing as below:

CHIX:OBSNz's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

ObsEva's EBIT for the three months ended in Dec. 2022 was CHF29.34 Mil.

ObsEva EBIT per Share Historical Data

The historical data trend for ObsEva's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva EBIT per Share Chart

ObsEva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT per Share

Get a 7-Day Free Trial

-1.90

-2.42

-1.43

-0.60

-0.21

ObsEva Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EBIT per Share	Get a 7-Day Free Trial															-0.16	-0.10	-0.36	-0.10	0.27

ObsEva EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

ObsEva's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-19.228	/	92.081
=	-0.21

ObsEva's EBIT per Share for the quarter that ended in Dec. 2022 is calculated as

	EBIT per Share		(Q: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	29.337	/	107.707
=	0.27

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.29

ObsEva (CHIX:OBSNz) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

ObsEva EBIT per Share Related Terms

Thank you for viewing the detailed overview of ObsEva's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ObsEva (CHIX:OBSNZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (CHIX:OBSNz) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228

Website

https://www.obseva.com

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva (CHIX:OBSNZ) Headlines

No Headlines